News

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...
Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...
In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.
The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.
The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...
While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...
Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.
A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...
Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...
In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.